Shubhanshu Shukla returning to Earth soon. Here's a recap of his 18 days onboard ISS
The SpaceX Dragon spacecraft, with Shukla and three other astronauts on the Axiom-4 Mission, undocked from the Harmony module of International Space Station (ISS) approximately 7.05 am EDT (4.35 pm IST) on Monday. The splashdown off the coast of California, US, is expected at 5.30 am EDT (3 PM IST) on Tuesday.
As his space expedition concludes, here's a recap of his 18-day-long journey onboard ISS.
On Sunday, the eve of the commencement of the Axiom-4 crew's return journey to Earth, Shukla evoked fellow astronaut Rakesh Sharma's line during the 1984 space odyssey and said today's India still looks 'saare Jahan se acha' and added 'India looks ambitious from space, today's India looks fearless, today's India looks confident, today's India looks full of pride.' During the farewell speech along with fellow astronauts, he said, 'Our journey ahead into space exploration may be long and arduous, but it has begun.'
Shukla, who conducted experiments on space microalgae, was live for the second and final time on ham radio on July 8 and remarked it was a privilege to be amongst the few who have had the chance to see the Earth from a vantage point. In a video posted on X handle, Shukla highlighted the significance of the mission and how it was expanding access to low Earth orbit (LEO) for countries to achieve their space exploration goals, leading to advancements for Earth. He also said how physical fitness is key to astronauts while at the ISS and that the orbiting observatory offers a mini gym for the astronauts. Shukla shared that his body, too, faced space sickness soon after reaching the ISS.
As Shukla called V Narayanan, Chairman of Indian Space Research Organisation, he acknowledged the efforts of team ISRO in ensuring his safe travel to ISS. While Narayanan expressed his keen interest in Shukla's well-being, he shared updates on the progress of the experiments and activities carried out on the space station.
In his first interaction with students from Thiruvananthapuram and Lucknow on ham radio on July 4, Shukla had a light-hearted conversation with the students he and narrated how difficult it was to sleep — not just because he was in space but owing to the excitement and wanting to do more and more experiments. Shukla, who showed students his sleeping bag, said, 'I am doing a lot of experiments and these are challenging and exciting. All of these experiments have been planned by ISRO-NASA. But there are a few that I particularly like, especially the one on stem cells. We know there is limited time (onboard the ISS) but we want to do more and more (experiments). But we need to get rest to do the experiments.'
Before that, his smiling photographs emerged from the cupola or the Earth-viewing vantage point and the Indian Air Force's (IAF) test pilot reiterated that looking back at the earth was beautiful and that it was an amazing experience.
Three days after Shukla ventured into space along with three other astronauts, Prime Minister Narendra Modi interacted with him and Shukla aka Shux discussed everything from pride he took in putting up the national flag on ISS, experiments onboard ISS, challenges of living in microgravity, in detail. PM Modi said he is close to the heart of his countrymen. 'Your name has the word 'shubh' in it and your journey is the 'shubharambh' of a new age,' he said.
The Air Force Group Captain also informed the Prime Minister that he had shared the 'gajar ka halwa', 'moong daal halwa', and 'aamras' with his fellow astronauts. 'I wanted others to taste and experience the rich culinary heritage of India. And they really enjoyed it,' he said.
Pilot Shukla — along with the commander Peggy Whitson and mission specialists Sławosz Uznański-Wiśniewski of Poland and Tibor Kapu of Hungary — entered the ISS on June 25. The Axiom-4 mission carrying the astronauts lifted off from Florida's Kennedy Space Centre, after facing several delays due to technical problems, inclement weather, and a leak on the ISS. Themed 'Realise the Return', this is the first stint of the astronauts from three countries on the ISS.
More than a month before the expedition, Shukla's family in Lucknow had an unusual company for dinner: Israeli astronaut Eytan Stibbe and he narrated everything on the space journey to his parents, alleviating their fears. Over a three-course dinner that lasted 3-4 hours at a hotel in Lucknow's Gomti Nagar, Stibbe — who was part of the historic Axiom-1 (Ax-1) mission to the ISS in 2022 – told Shukla's parents Shambhu Dayal Shukla and Asha, and sister Suchi, everything they needed to know: how astronauts lived, what they ate, how they slept, what they did, and how they spent their time at the ISS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
Time of India
an hour ago
- Time of India
Shubhanshu Shukla, Uznanski complete 1st brain-to-comp comms test in space, here's why it's important
As and the rest of the Ax-4 crew leave the International Space Station for their return to Earth, one of the lesser-known but groundbreaking experiments they carried out was 'PhotonGrav' by Polish neurotechnology firm Cortivision . Tired of too many ads? go ad free now In simple terms, it tested whether humans can communicate directly with a computer using nothing but their brain signals— for the first time ever in space. In an exclusive interview to TOI's , Wojciech Broniatowski , CEO & COO of Cortivision, spoke about the experiment, the challenges of brain monitoring in orbit, and why this matters for the future of spaceflight and life on Earth. Excerpts: Q: Can you explain the core objective of the 'PhotonGrav' experiment on Axiom-4, and how the microgravity environment supports or enhances your research? Allow me to start with a different question—can people communicate with a computer using only their brain? Would it work in space? It turns out, nobody had tried it. The core of our experiment was to prove the effectiveness of our technology in space by communicating with a machine without any muscle engagement. I know it sounds a bit complicated, even though the process is very simple. During the experiment, astronauts Shubhanshu Shukla and Sławosz Uznański performed mental calculation tasks. This means they put themselves in a deep focus state. Our fNIRS system detected changes in their brain activity and, using our AI, correctly identified whether they were focused or relaxed. On the surface, this seems simple. But if we look closer, the astronauts communicated simple signals—just by thinking—and the computer decoded their message correctly. This was the first time in history that humans communicated directly from their brain with a computer in space. Why microgravity? At Cortivision, we build products specifically designed for extreme environments. Microgravity is unique and very challenging, so if our technology works reliably there, it can handle any challenges on Earth. Tired of too many ads? go ad free now That makes microgravity testing crucial and a glimpse into the future of brain monitoring technologies. The International Space Station was the perfect place to prove that this fNIRS-based communication works in real space conditions—not just in a lab. And it worked perfectly. We hope this success will open the door for future collaborations with Indian space researchers, universities, and companies. Shux & Dariusz Zapała PhD from Cortivision during training Q: Why did Cortivision decide to conduct this specific experiment in space? In the autumn of 2023, Poland launched a call for projects to be done in orbit within the IGNIS mission, giving us a unique chance to push boundaries. At that time, we had already participated in two previous space missions (Ax-2 and Ax-3). We gained experience and understood the challenges astronauts face. So we seized this opportunity to demonstrate brain-computer communication in microgravity and continue developing technology for extreme environments. This mission was special for us because it involved a second Pole in space. You might think that science should be subject-agnostic, but in fact, it really matters who you work with on pioneering projects. Slawosz and Shux turned out to be perfect participants to carry such an ambitious experiment. Q: Of the four astronauts on Ax-4, Slawosz was a natural choice. But how and why was Shubhanshu Shukla chosen? Each mission includes a scientific programme. During training, astronauts meet with researchers who present various project proposals. The astronauts then sign up for experiments that interest them or that they feel comfortable with—this is how they express their willingness to participate. Our experiment seemed very appealing, but believe me, there were also projects that required more effort or caused discomfort. So the choice wasn't always straightforward. We were very keen to include as many astronauts as possible in our study. We're also hopeful to involve more crew members in future missions, since our equipment will remain on the ISS even after the current crew returns to Earth. The device Shukla and Uznanski used at ISS Q: Now that the Ax-4 crew has completed two weeks, what specific insights have you gained so far? How many trials did Shux and Slawosz run at the ISS? What did these trials entail? Please also elaborate on the findings. We can't reveal all the details yet, as the data is protected by personal privacy regulations and will be fully analysed before scientific publications are released. However, we can share that both Shubhanshu and Slawosz successfully completed the experiment three times in orbit. They achieved very strong results in detecting whether they were focused or relaxed. These mental states may sound abstract when we speak about communication—but if you think about the early days of computing, where communication was based on binary 'zeros' and 'ones,' it's actually a very similar principle. The astronauts, by changing their mental state, were sending a simple, clear signal that the system could recognise. What's important is that this was far from obvious. In microgravity, body fluids shift differently—this is why astronauts' faces often look swollen in space photos. These fluid shifts also affect how the brain's blood flow works, which could influence how well brain activation signals can be detected. That's why, before flying to the ISS, the astronauts carried out baseline measurements in Warsaw and Houston. After their return, they will do the same measurements again. This way, we'll be able to compare how the brain behaves on Earth and in orbit, and precisely assess the differences in our brain-computer interface communication performance. Q: Were there any unexpected results or anomalies observed during the experiment aboard the ISS that could shape future neurosensory or cognitive research in microgravity? Interestingly, after almost two years of preparation, the biggest surprise had nothing to do with the experiment itself—it was a simple technical glitch with the laptop on the ISS. The most advanced part—the brain-reading system—worked exactly as planned, while a regular piece of equipment gave us a little headache. It's a good reminder that sometimes the most complicated technologies run smoothly because they've been tested a thousand times, and it's the ordinary, everyday things that can surprise you. This experience shows why careful preparation is key, and why testing even the simplest parts of the setup is just as important as preparing the core science. Q: Have the results from Axiom-4 validated or challenged any of your pre-launch hypotheses, and how do you plan to apply this data in terrestrial applications or future missions? The results from the Ax-4 mission gave us a green light and confirmed what we had hoped for. Before the mission, we believed that fNIRS technology could be the best fit for space—more mobile and practical than fMRI, but giving deeper, more precise data than EEG. This mission proved that idea right. This means we now consider fNIRS ready for more advanced use in space—not only for brain-computer communication but also for monitoring astronauts' mental focus, improving their cognitive training, and supporting them in extreme isolation and stress. In the future, we may even be able to create personalised 'attention patterns' for each astronaut. By comparing their real-time focus to this personal pattern, we could detect when their attention drifts and help prevent mistakes during critical mission phases. And no, this has nothing to do with 'reading the mind'. We would only track physiological changes, so astronauts' dreams and thoughts are safe. On Earth, this technology has huge potential as well. We can use it for training pilots, surgeons, or anyone who needs to perform complex tasks under pressure. It could also be applied in neurorehabilitation or mental health monitoring. If our technology works in space—the harshest environment possible—it's certainly reliable in the demanding environments on Earth. Q: Explain how your device is different from the technologies already available on Earth. First, our technology wasn't built only for space. In fact, about 90 percent of what we do at Cortivision happens here on Earth. Universities, research centres, and clinical teams already use our fNIRS systems every day to study cognitive brain activity. Scientists don't have to fly to space to use it—our mission is to make advanced brain monitoring accessible in real-world conditions, whether it's a hospital, a lab, or a sports field. What makes our technology special is that it works in tough environments where traditional tools don't. EEG is lightweight but often noisy and uncomfortable in movement. fMRI gives great data but is huge and stationary. Our fNIRS system is the best of both worlds: it's portable and gives deep insights into how the brain uses oxygen during mental tasks—whether that's focus, stress, or fatigue. After three space missions, our device has been fully certified for safety by Nasa and remains on the ISS for future astronauts and scientists. Shubhanshu Shukla and Slawosz Uznański have already made history with it—but the device is still in orbit, ready for the next mission. Who will be next?
Time of India
an hour ago
- Time of India
BITM to livestream return of Shux
Kolkata: The Birla Industrial & Technological Museum will livestream the return of the Axiom Mission 4, piloted by group captain Shubhanshu Shukla. The event, scheduled to begin at 1.30 pm, will feature an open house quiz on spaceflight missions, an interactive science demonstration of rocket science involving Falcon 9 and Crew Dragon Grace Spacecraft, and a livestream of the spacecraft's re-entry into Earth's atmosphere with a splashdown off the coast of California in Pacific Ocean. Shukla and three crew members lifted off from Kennedy Space Centre in Florida on June 25 and docked to the International Space Station on June 26. Four months ago, Sunita Williams made a splashdown off the Florida coast in the Atlantic Ocean after the SpaceX Crew-9 capsule retrieved her and Butch Wilmore from the ISS, where she spent 278 days more than originally scheduled. BITM had livestreamed that event as well. tnn
